|
gptkbp:instanceOf
|
gptkb:drug
gonadotropin-releasing hormone antagonist
|
|
gptkbp:administeredBy
|
gptkb:follicle-stimulating_hormone
|
|
gptkbp:approvedBy
|
1990s
|
|
gptkbp:ATCCode
|
H01CC02
|
|
gptkbp:brand
|
gptkb:Orgalutran
|
|
gptkbp:CASNumber
|
124904-93-4
|
|
gptkbp:chemicalClass
|
peptide
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to ganirelix
|
|
gptkbp:developer
|
gptkb:Organon
|
|
gptkbp:effect
|
suppresses luteinizing hormone surge
prevents premature ovulation
|
|
gptkbp:eliminationHalfLife
|
13-16 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C81H112ClN17O14
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ganirelix
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits gonadotropin-releasing hormone receptor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
Category X (US)
|
|
gptkbp:proteinBinding
|
78%
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
injection site reaction
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:usedFor
|
in vitro fertilization
assisted reproduction
|
|
gptkbp:bfsParent
|
gptkb:Orgalutran
|
|
gptkbp:bfsLayer
|
6
|